Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Primary Open Angle Glaucoma and Netra Restoration Therapy
Primary Open Angle Glaucoma is a neurodegenerative optic nerve disease in which lowering eye pressure alone may not stop vision loss—Netra Restoration Therapy supports optic nerve health through ocular blood flow, neuroprotection, and reduced oxidative stress.
Request a Consultation
Lowering your IOP may not be enough to stop your Glaucoma vision loss. Neuroprotection, neurotrophins, ocular blood flow, ocular inflammation and oxidative stress can all contribute to your Glaucoma progression.
Why lowering IOP may not be enough to stop glaucoma vision loss?
Glaucoma is a neurodegenerative disease, not just a pressure disease
Glaucoma is increasingly understood as a neurodegenerative disease, not merely a condition caused by elevated eye pressure. This is particularly true in cases of Primary Open Angle Glaucoma. Mechanisms such as impaired ocular blood flow, mitochondrial dysfunction, oxidative stress, chronic inflammation, and reduced neurotrophic support, all of which contribute to neuronal injury.
Optic nerve damage isn't always caused by high eye pressure
While elevated intraocular pressure (IOP) is a major risk factor, many people develop glaucoma even with normal or low eye pressure—a condition known as normal-tension glaucoma (NTG). Recognizing primary open angle glaucoma as a neurodegenerative condition underscores the need for treatment strategies that go beyond pressure control and actively support optic nerve health and neuroprotection. If you seek a Glaucoma Specialist, our center provides these natural interventions.
Lowering IOP is important, but not always enough
Studies show that 30–40% of glaucoma patients continue to lose vision despite maintaining normal eye pressure. This highlights the need for a holistic approach to primary open angle glaucoma that goes beyond just IOP management. Finding the Best Glaucoma Specialist involves looking for a practitioner who treats the whole person, not just the eye pressure.
Individualized care is essential
Patients may require more than just IOP-lowering treatments. For instance, our glaucoma specialist New Jersey office uses neuroprotective strategies targeting the optic nerve. Treatments to improve ocular blood flow to the retina and optic nerve help reduce progression in primary open angle glaucoma.
What causes continued vision loss in glaucoma?
Multiple research studies have shown factors such as lack of neuroprotection, reduced ocular blood flow, neurotrophin deprivation, increased oxidative stress, ocular inflammation and excitotoxicity can all contribute to vision loss progression in Glaucoma.
Increased Intraocular Pressure (IOP) Is Not The Only Risk Factor For Glaucoma.
Lowering intraocular pressure (IOP) with eye drops has long been the standard approach. However, IOP control alone does not fully address the disease process. Many patients continue to experience optic nerve damage and vision loss despite well-controlled eye pressure. This highlights the need for a treatment strategy for primary open angle glaucoma that supports optic nerve health and addresses the biological factors beyond pressure alone.
Although reducing eye pressure (IOP) remains the standard of care for glaucoma, increased eye pressure alone does not fully explain the disease, and some individuals may continue to lose vision despite achieving target IOP levels.
What is Normal Tension Glaucoma?
Normal Tension Glaucoma (NTG) is a type of glaucoma in which optic nerve damage and vision loss occur despite eye pressure remaining within the normal range. In NTG, pressure alone does not explain the disease; instead, the optic nerve is thought to be more vulnerable due to factors such as reduced blood flow, impaired circulation regulation, increased nerve sensitivity, oxidative stress, and reduced neuroprotection. Because of this heightened susceptibility, even normal eye pressure can contribute to progressive damage over time.
The mean percentage of NTG in all patients diagnosed with a glaucomatous visual field defect is between 30% and 40%.
Asians and NTG
NTG is especially common in Asian populations, where it can account for a majority of primary open-angle glaucoma (POAG) cases—often exceeding 70–90%. This highlights that glaucoma is not solely a pressure-related condition, but a complex disease influenced by overall optic nerve health and systemic factors.
The prevalence of NTG has been reported to be 92.3% in Japan, 84.6% in Singapore, 83.58% in Northern China, 82% in South India, 79.3% in Southern China, 77% in South Korea, 57.1% in South Africa, 46.9% in Iran, 38.9% in Netherlands, 31.7% in the United States, 31.0% in Iceland, and 30.0% in Italy.
Source: Normal-Tension Glaucoma: Pathogenesis, Glaucoma Today, November/December 2022
Why NTG patients needs more than eye drops?
Normal Tension Glaucoma (NTG) patients often requires more than just eye-pressure–lowering drops because eye pressure is not their main cause of glaucomatous vision loss. In NTG, vision loss can occur even when eye pressure is normal, due to reduced blood flow to the optic nerve, poor regulation of blood vessels, increased inflammation, oxidative stress, and reduced support for the nerve cells that carry visual signals to the brain. While eye drops may help lower pressure slightly and remain part of treatment, they do not improve optic nerve blood flow or protect nerve cells from ongoing injury. For this reason, NTG care often needs a broader approach that supports optic nerve health, stabilizes blood flow, and addresses the underlying factors contributing to nerve damage—beyond eye pressure alone.
Netra Restoration Therapy (NRT)
Netra Restoration Therapy is an adjunctive, integrative program offered at Netra Eye Institute. For primary open-angle glaucoma, it is designed to support ocular perfusion, metabolic and oxidative-stress balance, and optic-nerve resilience while the patient continues pressure-lowering treatment and monitoring with a glaucoma specialist.
The intended mechanisms of Netra Restoration Therapy are support for ocular blood flow through vascular regulation, reduction of oxidative stress and ocular inflammation, support for neurotrophin signaling and neuroprotection, and reduction of ferroptosis-related injury. These are the biological targets of the program; the strength of evidence for each pathway varies and is discussed in the sections below.
Netra Restoration Therapy is designed to address ocular inflammation and oxidative stress, support ocular blood-flow regulation, and provide antioxidant and neuroprotective support to the eye. It is offered alongside, not instead of, ophthalmologist-directed glaucoma care, and it is not presented as a cure or as a guarantee of restored vision.
What NRT Aims to Support, and How It Is Measured
Glaucoma outcomes depend on baseline optic-nerve damage, intraocular-pressure control, rate of progression, adherence, and other risk factors. NRT is supportive care; it has not been established as a replacement for pressure-lowering drops, laser treatment, surgery, visual-field testing, or OCT monitoring, and individual outcomes vary.
Optic-Nerve Resilience
NRT addresses ocular inflammation, ocular blood-flow regulation and the nutritional environment of retinal cells, pathways associated with optic-nerve stress in glaucoma. Disease progression itself is tracked by your ophthalmologist through visual-field testing, OCT and pressure monitoring; NRT does not replace that monitoring.
Visual Field
Visual-field testing is one of the measures used to follow glaucoma over time. Where a baseline is available, changes during care are compared against it. Results vary between patients and no specific change is guaranteed.
Visual Acuity
Distance and near acuity are recorded at intake and at follow-up visits so that any change during care is documented. Acuity in glaucoma is often preserved until late disease, so it is one measure among several rather than the main endpoint.
Contrast Sensitivity
Contrast sensitivity, the ability to distinguish shapes, edges and detail against similar backgrounds, is frequently affected in glaucoma and is assessed as part of the functional-vision review.
Brightness, Color and Low-Light Function
Patients are asked about brightness perception, color, and low-light or night-time function, because these affect mobility and daily activities and are not captured by an acuity chart alone.
Glare and Light Sensitivity
Glare, light sensitivity and comfort in bright environments such as sunlight, headlights and digital screens are recorded at each visit as part of the functional-vision review.
Eye Strain and Discomfort
Eye strain and ocular discomfort are documented at each visit as reported by the patient, alongside the objective measures above.
Overall Well-Being
Because NRT is a whole-person program, general well-being is discussed alongside eye-specific measures. Individual experiences vary and are not a predictor of visual outcomes.
NRT backed by scientific research studies
Netra Restoration Therapy is grounded in contemporary biomedical research demonstrating that many eye diseases are driven by reduced ocular blood flow, ongoing neurodegeneration, and cellular stress. Scientific studies show that improving vascular regulation enhances oxygen and nutrient delivery to the retina and optic nerve, while supporting neurotrophin activity and neuroprotection helps preserve vulnerable nerve cells. At the same time, controlling oxidative stress, ferroptosis, and chronic inflammation is critical to slowing tissue damage and disease progression. Netra Restoration integrates these evidence-based principles into a comprehensive approach designed to support long-term eye health and visual function.
Frequently Asked Questions on Primary Open Angle Glaucoma
Primary Open Angle Glaucoma is a chronic optic neuropathy in which the drainage angle remains open, but the optic nerve gradually develops characteristic damage.
No. Elevated intraocular pressure is an important risk factor, but POAG is multifactorial. Ocular blood flow, optic nerve susceptibility, mitochondrial dysfunction, oxidative stress, inflammation, neurotrophin deprivation, genetics, age, vascular health, and systemic terrain may all influence disease behavior.
Netra Restoration Therapy is an adjunctive integrative ophthalmology approach designed to support optic nerve resilience by addressing ocular blood flow, neuroprotection, mitochondrial function, oxidative stress, inflammatory balance, neurotrophic signaling, autonomic regulation, and whole-body factors that may influence glaucoma.
No. NRT is not a cure for glaucoma and should not be presented as one. It is a supportive, adjunctive approach designed to improve the biological environment associated with optic nerve health.
No. Patients with POAG should continue regular eye examinations, pressure monitoring, visual field testing, OCT imaging, optic nerve evaluation, and ophthalmologist-directed care. NRT is complementary and does not replace medical monitoring.
NRT should not be marketed as a guaranteed pressure-lowering therapy. Its primary emphasis is broader optic nerve terrain support, including blood flow, neuroprotection, oxidative stress reduction, inflammation balance, mitochondrial function, and systemic resilience.
The optic nerve requires stable oxygen and nutrient delivery. Low ocular perfusion pressure, vascular dysregulation, and endothelial dysfunction may increase optic nerve vulnerability. Ocular blood-flow support is therefore a major part of NRT's integrative glaucoma model.
Oxidative stress may affect the trabecular meshwork, retinal ganglion cells, mitochondria, vascular endothelium, and glial cells. Long-term oxidative burden can amplify inflammation, impair outflow tissue, and reduce neural resilience.
Retinal ganglion cells have high mitochondrial demand. Mitochondrial dysfunction can reduce ATP production, increase reactive oxygen species, impair calcium regulation, and make retinal ganglion cells more vulnerable to stress.
BDNF and NGF are neurotrophic factors involved in neural survival, repair, and resilience. Research suggests that impaired neurotrophic signaling and axonal transport may contribute to retinal ganglion cell vulnerability in glaucoma.
Glutamate excitotoxicity refers to neuronal injury caused by excessive glutamate signaling and calcium overload. In glaucoma, it is considered one possible contributor to retinal ganglion cell stress, especially when combined with ischemia, oxidative stress, and inflammation.
Ferroptosis is an iron-dependent form of regulated cell death involving lipid peroxidation. Emerging glaucoma research links ferroptosis with oxidative stress, mitochondrial dysfunction, excitotoxicity, and retinal ganglion cell death.
The gut-eye axis describes the relationship between gut microbiome balance, systemic inflammation, immune signaling, and eye disease. Early research suggests that gut dysbiosis and immune activation may influence glaucoma biology, but this field is still developing.
Patients with Primary Open Angle Glaucoma who want adjunctive support for optic nerve resilience, ocular perfusion, mitochondrial health, inflammation balance, and whole-body terrain may consider NRT after individualized evaluation.
Sudden vision loss, eye pain, severe headache, halos around lights, sudden redness, rapid field loss, or any abrupt change in vision should be evaluated promptly by an eye-care professional.
Selected References for Scientific Support
- Mahabadi N, Foris LA, Tripathy K. "Open Angle Glaucoma." StatPearls. Updated 2024.
- Weinreb RN, Aung T, Medeiros FA. "The pathophysiology and treatment of glaucoma: a review." JAMA. 2014;311(18):1901-1911.
- Weinreb RN, Leung CKS, Crowston JG, et al. "Primary open-angle glaucoma." Nature Reviews Disease Primers. 2016;2:16067.
- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. "Global prevalence of glaucoma and projections of glaucoma burden through 2040." Ophthalmology. 2014;121(11):2081-2090.
- Tezel G. "Oxidative stress in glaucomatous neurodegeneration." Progress in Retinal and Eye Research. 2006;25(5):490-513.
- Vernazza S, Oddone F, Tirendi S, et al. "Risk factors for retinal ganglion cell distress in glaucoma and neuroprotective potential intervention." International Journal of Molecular Sciences. 2021;22(15):7994.
- Duarte JN. "Neuroinflammatory mechanisms of mitochondrial dysfunction and neurodegeneration in glaucoma." Journal of Ophthalmology. 2021.
- Quigley HA, McKinnon SJ, Zack DJ, et al. "Retrograde axonal transport of BDNF in retinal ganglion cells is inhibited by acute IOP elevation in rats." Investigative Ophthalmology & Visual Science. 2000;41(11):3460-3466.
- Johnson EC, Morrison JC. "Neurotrophin roles in retinal ganglion cell survival: lessons from glaucoma." Experimental Eye Research. 2009;88(4):808-815.
- Lambuk L, et al. "Brain-derived neurotrophic factor-mediated neuroprotection in glaucoma." 2022.
- Christensen I, Lu B, Yang N, et al. "The susceptibility of retinal ganglion cells to glutamatergic excitotoxicity is type-specific." Frontiers in Neuroscience. 2019;13:219.
- Kim KE, Oh S, Baek SU, et al. "Ocular perfusion pressure and the risk of open-angle glaucoma: systematic review and meta-analysis." Scientific Reports. 2020;10:10056.
- Zhou W, et al. "Vascular dysregulation in glaucoma: retinal vasoconstriction and altered vascular response." EPMA Journal. 2023.
- Qin M, et al. "Ferroptosis and retinal ganglion cell death in glaucoma." 2025.
- Krilis M, Fry L, Ngo P, Goldberg I. "The gut microbiome and primary open angle glaucoma: evidence for a gut-glaucoma axis?" European Journal of Ophthalmology. 2024;34(4):1100-1108.
- Liao YF, et al. "Acupuncture as adjuvant therapy for glaucoma." 2024.
- Yang J, et al. "Integrating network pharmacological and experimental validation to investigate traditional Chinese medicine mechanisms in glaucoma." Evidence-Based Complementary and Alternative Medicine. 2021.
- Boia R, et al. "Neuroprotective strategies for retinal ganglion cell degeneration." 2020.
From the research
Glaucoma is not only about eye pressure: a million-man UK study links erectile dysfunction to higher glaucoma risk
A 2026 study in the British Journal of Ophthalmology adds to the evidence that blood-vessel health plays a part in open-angle glaucoma. Our clinical team reviews what it found and what it means.